Reporting from ESMO Congress 2023 in Madrid, Linda Mileshkin discusses the results from two trials focusing on genomics profiling in the diagnosis and treatment of patients with Cancer of Unknown Primary.
Abstracts discussed:
- LBA16 - Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP), presented by L. Mileshkin
- LBA100 - CUP-ONE Trial: A prospective double-blind validation of molecular classifiers in the diagnosis of Cancer of Unknown Primary and clinical outcomes, presented by H.S. Wasan